GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TuHURA Biosciences Inc (NAS:HURA) » Definitions » Short-Term Debt & Capital Lease Obligation

HURA (TuHURA Biosciences) Short-Term Debt & Capital Lease Obligation : $0.17 Mil (As of Mar. 2025)


View and export this data going back to 2024. Start your Free Trial

What is TuHURA Biosciences Short-Term Debt & Capital Lease Obligation?

Short-Term Debt & Capital Lease Obligation is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt. TuHURA Biosciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was $0.17 Mil.

Long-Term Debt & Capital Lease Obligation is the debt and capital lease obligation due more than 12 months in the future. TuHURA Biosciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was $0.00 Mil.


TuHURA Biosciences Short-Term Debt & Capital Lease Obligation Historical Data

The historical data trend for TuHURA Biosciences's Short-Term Debt & Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TuHURA Biosciences Short-Term Debt & Capital Lease Obligation Chart

TuHURA Biosciences Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Short-Term Debt & Capital Lease Obligation
0.64 0.12 0.02 0.16

TuHURA Biosciences Quarterly Data
Dec21 Mar22 Dec22 Mar23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Short-Term Debt & Capital Lease Obligation Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.15 0.15 - 0.16 0.17

TuHURA Biosciences Short-Term Debt & Capital Lease Obligation Calculation

This is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt.

In the notes to balance sheet in annual (10-K) or quarterly (10-Q) reports, companies usually break down the details of the debt, their due dates, the interest rates etc.


Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term


TuHURA Biosciences Short-Term Debt & Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of TuHURA Biosciences's Short-Term Debt & Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.


TuHURA Biosciences Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TuHURA Biosciences Inc (NAS:HURA) » Definitions » Short-Term Debt & Capital Lease Obligation
Traded in Other Exchanges
Address
10500 University Center Drive, Suite 110, Tampa, FL, USA, 33612
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.

TuHURA Biosciences Headlines

From GuruFocus